Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab Long-term Extension in Pediatric Osteogenesis Imperfecta
NCT03638128Phase 3Terminated
- Sponsor
- Amgen
- Start
- Jul 2018
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, open-label trial of denosumab in osteogenesis imperfecta (OI) (3 arms), sponsored by Amgen. Primary endpoints: Number of Participants With Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest up to 24 months, Number of Participants With Anti-denosumab Antibodies up to 24 months and 5 more. Started Jul 2018; status: terminated.
02
Drugs
denosumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT03638128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638128.